5Ponti F,Poluzzi E,Montanaro N.Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs:a call for consensus[J].Eur J Clin Pharmacol,2001,57(3):185-209.
3[2]Ram CV.Review of resistant hypertension[J].Curt Hypertens Rep,2006,8(5):398-402.
4[3]Park J,Campese V.Clinical eharaeteristies of resistant hypertension:the importance of compliance and the role of diagnostic evaluation in delineating pathogenesis[J].J Clin Hypertens,2007,9(lsuppl 1):7-12.
5[4]Papadopoulos DP,Papademetriou V.Resistant hypertension:diagnosis and management[J].J Cardiovasc Pharmaeol and Therap,2006,11(2):113-118.
6[5]The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).2007 Guidelines for the management of arterial hypertension[J].J Hypertents,2007,25(6):1105-1187.
8[9]Khan NA,Hemmelgam B,Padwal R,et al.The 2007 Canadian hypertension education program recommendations for the management of hypertension:Part 2-therapy[J].Can J Cardiol,2007,23(7):539-550.
9[10]Chobanian AV,Bakris GL,Black HR,et al.Seventh report of the Joint National Committee on prevention,detection,evaluation and treatment of high blood pressure[J].Hypertension,2003,42(6):1206-1252.
10[11]Japanese Society Hypertension.Japanese Society Hypertension guidelines for the management of hypertension(JSH 2004)[J].Hypertens,2006,29(Suppl):Sl-105.
